Table 1.

Baseline characteristics of enrolled patients who received OBP-301 for hepatocellular carcinoma

	Cohort 1 N = 3	Cohort 2 N = 3	Cohort 3 N = 3	Cohort 4 N = 3	Cohort 5 N = 8	Total N = 20
Age at enrollment (years)	61.34 (49.6–62.8)	55.23 (48.4–61.9)	53.15 (50.6–63.2)	59.10 (50.0–62.2)	60.69 (57.1–65.9)	59.39 (48.4–65.9)
Duration since HCC diagnosis (years)	3.73 (3.0–7.3)	1.19 (0.2–1.4)	6.00 (2.3–8.3)	3.12 (1.5–3.4)	4.97 (1.5–7.6)	3.24 (0.2–8.3)
Gender
Male	3 (100.0)	2 (66.7)	3 (100.0)	2 (66.7)	8 (100.0)	18 (90.0)
Female	0	1 (33.3)	0	1 (33.3)	0	2 (10.0)
Ethnicity
Chinese	2 (66.7)	1 (33.3)	1 (33.3)	1 (33.3)	1 (12.5)	6 (30.0)
Korean	1 (33.3)	2 (66.7)	2 (66.7)	2 (66.7)	7 (87.5)	14 (70.0)
Barcelona Clinic Liver Cancer stage
Stage B	2 (66.7)	1 (33.3)	2 (66.7)	1 (33.3)	1 (12.5)	7 (35.0)
Stage C	1 (33.3)	2 (66.7)	1 (33.3)	2 (66.7)	7 (87.5)	13 (65.0)
ECOG performance score
0	2 (66.7)	3 (100.0)	2 (66.7)	1 (33.3)	2 (25.0)	10 (50.0)
1	1 (33.3)	0	1 (33.3)	2 (66.7)	5 (62.5)	9 (45.0)
2	0	0	0	0	1 (12.5)	1 (5.0)
3	0	0	0	0	0	0
4	0	0	0	0	0	0
Child-Pugh status
5	3 (100.0)	3 (100.0)	2 (66.7)	2 (66.7)	7 (87.5)	17 (85.0)
6	0	0	1 (33.3)	1 (33.3)	1 (12.5)	3 (15.0)
7	0	0	0	0	0	0
Alpha-fetoprotein (ng/mL)
≥400	1 (33.3)	2 (66.7)	1 (33.3)	1 (33.3)	5 (62.5)	10 (50.0)
<400	2 (66.7)	1 (33.3)	2 (66.7)	2 (66.7)	3 (37.5)	10 (50.0)
Hepatitis B and hepatitis C screening
HBV-positive	3 (100.0)	3 (100.0)	3 (100.0)	3 (100.0)	7 (87.5)	19 (95.0)
HCV-positive	0	0	0	0	1 (12.5)	1 (5.0)
Previous treatment (TACE and/or sorafenib)
Yes	3 (100.0)	3 (100.0)	3 (100.0)	3 (100.0)	8 (100.0)	20 (100.0)
No	0	0	0	0	0	0
Size of largest target tumor (cm)	2.00 (1.8–3.0)	4.00 (2.4–8.1)	2.30 (2.2–2.7)	2.50 (2.4–3.3)	4.45 (2.1–7.6)	2.85 (1.8–8.1)
Total cumulative dose (×1010 VP/tumor)	1.00 (1.0–1.0)	10 (10.0–10.0)	100 (100–100)	300 (300–300)	600 (200–600)

Numbers indicate median (range) or N (% of patients).